Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

MD vs DBVT vs THC vs ALKS vs HCA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
MD
Pediatrix Medical Group, Inc.

Medical - Care Facilities

HealthcareNYSE • US
Market Cap$1.90B
5Y Perf.+47.6%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.-58.8%
THC
Tenet Healthcare Corporation

Medical - Care Facilities

HealthcareNYSE • US
Market Cap$17.01B
5Y Perf.+792.1%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+116.4%
HCA
HCA Healthcare, Inc.

Medical - Care Facilities

HealthcareNYSE • US
Market Cap$95.95B
5Y Perf.+301.5%

MD vs DBVT vs THC vs ALKS vs HCA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
MD logoMD
DBVT logoDBVT
THC logoTHC
ALKS logoALKS
HCA logoHCA
IndustryMedical - Care FacilitiesBiotechnologyMedical - Care FacilitiesBiotechnologyMedical - Care Facilities
Market Cap$1.90B$1712.35T$17.01B$5.90B$95.95B
Revenue (TTM)$1.93B$0.00$21.45B$1.56B$75.60B
Net Income (TTM)$174M$-168M$1.70B$153M$6.78B
Gross Margin25.5%42.8%65.4%41.5%
Operating Margin11.9%16.1%12.3%15.8%
Forward P/E10.3x10.9x24.8x14.2x
Total Debt$660M$22M$13.17B$70M$50.20B
Cash & Equiv.$375M$194M$2.88B$1.12B$1.04B

MD vs DBVT vs THC vs ALKS vs HCALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

MD
DBVT
THC
ALKS
HCA
StockMay 20May 26Return
Pediatrix Medical G… (MD)100147.6+47.6%
DBV Technologies S.… (DBVT)10041.2-58.8%
Tenet Healthcare Co… (THC)100892.1+792.1%
Alkermes plc (ALKS)100216.4+116.4%
HCA Healthcare, Inc. (HCA)100401.5+301.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: MD vs DBVT vs THC vs ALKS vs HCA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HCA leads in 4 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. DBV Technologies S.A. is the stronger pick specifically for recent price momentum and sentiment. THC and ALKS also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
MD
Pediatrix Medical Group, Inc.
The Lower-Volatility Pick

Among these 5 stocks, MD doesn't own a clear edge in any measured category.

Best for: healthcare exposure
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT is the #2 pick in this set and the best alternative if momentum is your priority.

  • +110.4% vs ALKS's +16.5%
Best for: momentum
THC
Tenet Healthcare Corporation
The Long-Run Compounder

THC ranks third and is worth considering specifically for long-term compounding and valuation efficiency.

  • 5.2% 10Y total return vs HCA's 450.5%
  • PEG 0.33 vs HCA's 0.67
  • Beta 0.71, current ratio 1.76x
  • Lower P/E (10.9x vs 14.2x), PEG 0.33 vs 0.67
Best for: long-term compounding and valuation efficiency
ALKS
Alkermes plc
The Defensive Pick

ALKS is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • 9.8% margin vs DBVT's 0.3%
Best for: sleep-well-at-night
HCA
HCA Healthcare, Inc.
The Income Pick

HCA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 5 yrs, beta 0.29, yield 0.7%
  • Rev growth 7.1%, EPS growth 29.0%, 3Y rev CAGR 7.9%
  • 7.1% revenue growth vs DBVT's -100.0%
  • Beta 0.29 vs DBVT's 1.26
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthHCA logoHCA7.1% revenue growth vs DBVT's -100.0%
ValueTHC logoTHCLower P/E (10.9x vs 14.2x), PEG 0.33 vs 0.67
Quality / MarginsALKS logoALKS9.8% margin vs DBVT's 0.3%
Stability / SafetyHCA logoHCABeta 0.29 vs DBVT's 1.26
DividendsHCA logoHCA0.7% yield; 5-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)DBVT logoDBVT+110.4% vs ALKS's +16.5%
Efficiency (ROA)HCA logoHCA11.3% ROA vs DBVT's -89.0%

MD vs DBVT vs THC vs ALKS vs HCA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

MDPediatrix Medical Group, Inc.
FY 2025
Health Care, Patient Service
85.2%$1.6B
Hospitals Contracts
14.2%$271M
Product and Service, Other
0.6%$12M
DBVTDBV Technologies S.A.

Segment breakdown not available.

THCTenet Healthcare Corporation
FY 2025
Ambulatory Care
50.2%$5.2B
Hospital Operations
49.8%$5.1B
ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
HCAHCA Healthcare, Inc.
FY 2025
Managed Care And Other Insurers
50.5%$37.0B
Managed Medicare
18.4%$13.4B
Medicare
15.4%$11.3B
Medicaid
8.1%$5.9B
Managed Medicaid
5.0%$3.7B
International
2.5%$1.9B

MD vs DBVT vs THC vs ALKS vs HCA — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLTHCLAGGINGDBVT

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 4 of 6 comparable metrics.

HCA and DBVT operate at a comparable scale, with $75.6B and $0 in trailing revenue. Profitability is closely matched — net margins range from 9.8% (ALKS) to 7.9% (THC). On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricMD logoMDPediatrix Medical…DBVT logoDBVTDBV Technologies …THC logoTHCTenet Healthcare …ALKS logoALKSAlkermes plcHCA logoHCAHCA Healthcare, I…
RevenueTrailing 12 months$1.9B$0$21.5B$1.6B$75.6B
EBITDAEarnings before interest/tax$252M-$112M$4.3B$212M$15.5B
Net IncomeAfter-tax profit$174M-$168M$1.7B$153M$6.8B
Free Cash FlowCash after capex$238M-$151M$3.3B$392M$7.7B
Gross MarginGross profit ÷ Revenue+25.5%+42.8%+65.4%+41.5%
Operating MarginEBIT ÷ Revenue+11.9%+16.1%+12.3%+15.8%
Net MarginNet income ÷ Revenue+9.0%+7.9%+9.8%+9.0%
FCF MarginFCF ÷ Revenue+12.3%+15.6%+25.1%+10.2%
Rev. Growth (YoY)Latest quarter vs prior year+3.9%+2.8%+28.2%+6.7%
EPS Growth (YoY)Latest quarter vs prior year+50.0%+91.5%+87.6%-4.1%+44.6%
ALKS leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

THC leads this category, winning 4 of 7 comparable metrics.

At 11.8x trailing earnings, MD trades at a 52% valuation discount to ALKS's 24.8x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.38x vs HCA's 0.72x — a lower PEG means you pay less per unit of expected earnings growth.

MetricMD logoMDPediatrix Medical…DBVT logoDBVTDBV Technologies …THC logoTHCTenet Healthcare …ALKS logoALKSAlkermes plcHCA logoHCAHCA Healthcare, I…
Market CapShares × price$1.9B$1712.35T$17.0B$5.9B$95.9B
Enterprise ValueMkt cap + debt − cash$2.2B$1712.35T$27.3B$4.9B$145.1B
Trailing P/EPrice ÷ TTM EPS11.82x-0.76x12.53x24.76x15.12x
Forward P/EPrice ÷ next-FY EPS est.10.26x10.94x14.19x
PEG RatioP/E ÷ EPS growth rate0.38x0.72x
EV / EBITDAEnterprise value multiple8.66x6.34x17.25x9.37x
Price / SalesMarket cap ÷ Revenue1.00x0.80x4.00x1.27x
Price / BookPrice ÷ Book value/share2.26x0.66x1.97x3.28x
Price / FCFMarket cap ÷ FCF7.54x6.72x12.28x12.47x
THC leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

Evenly matched — ALKS and HCA each lead in 4 of 9 comparable metrics.

MD delivers a 20.1% return on equity — every $100 of shareholder capital generates $20 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to THC's 1.47x. On the Piotroski fundamental quality scale (0–9), MD scores 7/9 vs DBVT's 4/9, reflecting strong financial health.

MetricMD logoMDPediatrix Medical…DBVT logoDBVTDBV Technologies …THC logoTHCTenet Healthcare …ALKS logoALKSAlkermes plcHCA logoHCAHCA Healthcare, I…
ROE (TTM)Return on equity+20.1%-130.2%+19.6%+8.8%
ROA (TTM)Return on assets+8.1%-89.0%+5.7%+5.4%+11.3%
ROICReturn on invested capital+14.8%+13.2%+18.9%+19.9%
ROCEReturn on capital employed+13.2%-145.7%+13.8%+14.2%+27.0%
Piotroski ScoreFundamental quality 0–974777
Debt / EquityFinancial leverage0.76x0.13x1.47x0.04x
Net DebtTotal debt minus cash$285M-$172M$10.3B-$1.0B$49.2B
Cash & Equiv.Liquid assets$375M$194M$2.9B$1.1B$1.0B
Total DebtShort + long-term debt$660M$22M$13.2B$70M$50.2B
Interest CoverageEBIT ÷ Interest expense20.20x-189.82x4.28x32.30x5.37x
Evenly matched — ALKS and HCA each lead in 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

THC leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in THC five years ago would be worth $29,044 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs ALKS's +16.5%. The 3-year compound annual growth rate (CAGR) favors THC at 40.7% vs ALKS's 4.6% — a key indicator of consistent wealth creation.

MetricMD logoMDPediatrix Medical…DBVT logoDBVTDBV Technologies …THC logoTHCTenet Healthcare …ALKS logoALKSAlkermes plcHCA logoHCAHCA Healthcare, I…
YTD ReturnYear-to-date+7.7%+4.9%-2.7%+25.3%-8.6%
1-Year ReturnPast 12 months+59.8%+110.4%+27.4%+16.5%+19.7%
3-Year ReturnCumulative with dividends+67.0%+19.7%+178.5%+14.5%+57.4%
5-Year ReturnCumulative with dividends-28.6%-69.1%+190.4%+60.9%+109.7%
10-Year ReturnCumulative with dividends-67.1%-87.0%+523.4%-11.0%+450.5%
CAGR (3Y)Annualised 3-year return+18.6%+6.2%+40.7%+4.6%+16.3%
THC leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ALKS and HCA each lead in 1 of 2 comparable metrics.

HCA is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricMD logoMDPediatrix Medical…DBVT logoDBVTDBV Technologies …THC logoTHCTenet Healthcare …ALKS logoALKSAlkermes plcHCA logoHCAHCA Healthcare, I…
Beta (5Y)Sensitivity to S&P 5000.73x1.26x0.71x1.06x0.29x
52-Week HighHighest price in past year$24.99$26.18$247.21$36.60$556.52
52-Week LowLowest price in past year$11.84$7.53$146.60$25.17$330.00
% of 52W HighCurrent price vs 52-week peak+91.8%+76.3%+78.5%+96.7%+77.1%
RSI (14)Momentum oscillator 0–10051.348.152.960.230.8
Avg Volume (50D)Average daily shares traded772K252K1.2M2.3M1000K
Evenly matched — ALKS and HCA each lead in 1 of 2 comparable metrics.

Analyst Outlook

HCA leads this category, winning 1 of 1 comparable metric.

Analyst consensus: MD as "Hold", DBVT as "Buy", THC as "Buy", ALKS as "Buy", HCA as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs -3.0% for MD (target: $22). HCA is the only dividend payer here at 0.69% yield — a key consideration for income-focused portfolios.

MetricMD logoMDPediatrix Medical…DBVT logoDBVTDBV Technologies …THC logoTHCTenet Healthcare …ALKS logoALKSAlkermes plcHCA logoHCAHCA Healthcare, I…
Analyst RatingConsensus buy/hold/sellHoldBuyBuyBuyBuy
Price TargetConsensus 12-month target$22.25$46.33$268.00$44.00$527.45
# AnalystsCovering analysts3315322846
Dividend YieldAnnual dividend ÷ price+0.7%
Dividend StreakConsecutive years of raises0005
Dividend / ShareAnnual DPS$2.94
Buyback YieldShare repurchases ÷ mkt cap+4.6%0.0%+8.4%+0.5%+10.5%
HCA leads this category, winning 1 of 1 comparable metric.
Key Takeaway

THC leads in 2 of 6 categories (Valuation Metrics, Total Returns). ALKS leads in 1 (Income & Cash Flow). 2 tied.

Best OverallTenet Healthcare Corporation (THC)Leads 2 of 6 categories
Loading custom metrics...

MD vs DBVT vs THC vs ALKS vs HCA: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is MD or DBVT or THC or ALKS or HCA a better buy right now?

For growth investors, HCA Healthcare, Inc.

(HCA) is the stronger pick with 7. 1% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Pediatrix Medical Group, Inc. (MD) offers the better valuation at 11. 8x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — MD or DBVT or THC or ALKS or HCA?

On trailing P/E, Pediatrix Medical Group, Inc.

(MD) is the cheapest at 11. 8x versus Alkermes plc at 24. 8x. On forward P/E, Pediatrix Medical Group, Inc. is actually cheaper at 10. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 33x versus HCA Healthcare, Inc. 's 0. 67x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — MD or DBVT or THC or ALKS or HCA?

Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +190.

4%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: THC returned +523. 4% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — MD or DBVT or THC or ALKS or HCA?

By beta (market sensitivity over 5 years), HCA Healthcare, Inc.

(HCA) is the lower-risk stock at 0. 29β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 339% more volatile than HCA relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 147% for Tenet Healthcare Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — MD or DBVT or THC or ALKS or HCA?

By revenue growth (latest reported year), HCA Healthcare, Inc.

(HCA) is pulling ahead at 7. 1% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Pediatrix Medical Group, Inc. grew EPS 263. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — MD or DBVT or THC or ALKS or HCA?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is MD or DBVT or THC or ALKS or HCA more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 33x versus HCA Healthcare, Inc. 's 0. 67x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pediatrix Medical Group, Inc. (MD) trades at 10. 3x forward P/E versus 14. 2x for HCA Healthcare, Inc. — 3. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — MD or DBVT or THC or ALKS or HCA?

In this comparison, HCA (0.

7% yield) pays a dividend. MD, DBVT, THC, ALKS do not pay a meaningful dividend and should not be held primarily for income.

09

Is MD or DBVT or THC or ALKS or HCA better for a retirement portfolio?

For long-horizon retirement investors, HCA Healthcare, Inc.

(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Both have compounded well over 10 years (HCA: +450. 5%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between MD and DBVT and THC and ALKS and HCA?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MD is a small-cap deep-value stock; DBVT is a mega-cap quality compounder stock; THC is a mid-cap deep-value stock; ALKS is a small-cap quality compounder stock; HCA is a mid-cap deep-value stock. HCA pays a dividend while MD, DBVT, THC, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

MD

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

THC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

HCA

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.